German startup Pieris hopes they could prove a cheaper alternative to antibodies. (Click here for company profile.) The structure of lipocalins was first elucidated during the early 1980s ...

(Pieris). The combined company will operate under the name Palvella Therapeutics, Inc., and its shares are expected to begin trading on the Nasdaq Capital Market on December 16, 2024, under the ...

The focus of the combined company is developing new treatment for rare genetic skin diseases. Palvella Therapeutics completed a reverse merger with Pieris Pharmaceutical of Boston to become a ...